Gene study aims to sharpen malaria pill dosing
NCT ID NCT07373743
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how different genetic makeups affect the way healthy adults process the malaria prevention drug tafenoquine (ARAKODA). Researchers will measure drug levels in blood and urine over time, along with safety checks. The goal is to better understand how to dose the drug for different people. The study involves 20 healthy adults aged 18-65.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETIC IN NORMAL POPULATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
SUNY Upstate Medical University, Upstate Global Health Institute
East Syracuse, New York, 13057, United States
Contact Email: •••••@•••••